Compare
Lexeo Therapeutics, Inc. vs Tectonic Therapeutic, Inc. vs Coherus Oncology, Inc. vs X4 Pharmaceuticals, Inc
| Latest fiscal year | Lexeo Therapeutics, Inc. LXEO | Tectonic Therapeutic, Inc. TECX | Coherus Oncology, Inc. CHRSRevenue covers only part of its income (partial revenue) | X4 Pharmaceuticals, Inc XFOR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $35.11M |
| Revenue growth (YoY) | n/a | n/a | n/a | n/m |
| Gross margin | n/a | n/a | n/a | 83.6% (computed) |
| Operating margin | n/a | n/a | n/a | -247.4% |
| Net margin | n/a | n/a | n/a | -225.6% |
| Net income | -$99.96M | -$74.15M | $168.02M | -$79.20M |
| EPS (Diluted) | -$1.86 | -$4.05 | $1.43 | -$1.87 |
| Operating cash flow | -$98.56M | -$60.08M | -$138.51M | -$85.62M |
| Free cash flow | -$98.96M | -$60.29M | n/a | -$85.62M |
| Cash & equivalents | $63.00M | $253.80M | $88.88M | $217.05M |
| Total assets | $268.69M | $261.04M | $258.34M | $290.46M |
| Total liabilities | $22.02M | $9.71M | $197.33M | $104.17M |
| Shareholders' equity | $246.67M | $251.33M | $61.01M | $186.29M |
| Return on year-end equity | -40.5% | -29.5% | 275.4% | -42.5% |
| Shares outstanding | 73.00M | 18.74M | 121.15M | 90.91M |
Revenue, most recent five fiscal years
| Fiscal year | Lexeo Therapeutics, Inc. | Tectonic Therapeutic, Inc. | Coherus Oncology, Inc. | X4 Pharmaceuticals, Inc |
|---|---|---|---|---|
| Latest | $654.0K Ended 2022-12-31 | n/a | n/a | $35.11M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $2.56M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $0 Ended 2021-12-31 |